Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report.

Anti-cancer drugs - 1 Oct 2022

Zhang Fan, Li Xiaomin, Liu Haisheng, Liu Rongfeng, Zhou Zhiguo, Zhang Yi, Chen Jingli, Tian Ye, Pan Chaohu, Meng Qingju, Liu Yibing

Abstract excerpt

The reason that immune checkpoint inhibitors have not been widely applied to pancreatic cancer treatment is probably because of low immunogenicity or dense stromal fibrosis. Recently, only pembrolizumab was recommended for DNA mismatch repair deficiency or high microsatellite instability by National Comprehensive Cancer Network guideline. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35946538
DOI: 10.1097/CAD.0000000000001334
PMCID: PMC9481288

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report.PMID 35946538Read ↗

PD-1 blockade plus capecitabine as curative-intent treatment for tumor mutational burden-high multi-metastatic pancreatic ductal adenocarcinoma: A case reportSemantic proximity Read ↗

Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.Semantic proximity Read ↗

Severe Rashes Associated With Immunotherapy and Gene Mutations in a Patient With Metastatic Pancreatic CancerSemantic proximity Read ↗

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkersSemantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.Semantic proximity Read ↗

A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case reportSemantic proximity Read ↗

Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.Semantic proximity Read ↗

New therapeutic targets in pancreatic cancer.Semantic proximity Read ↗

Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?Semantic proximity Read ↗

Emerging Treatment Strategies in Pancreatic Cancer.Semantic proximity Read ↗

Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.